Skip to search formSkip to main contentSkip to account menu

GS-9190

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tegobuvir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance.
2013
2013
Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451
ABSTRACT GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1… 
2012
2012
Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a.
Highly Cited
2011
Highly Cited
2011
Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
ABSTRACT GS-9190 (Tegobuvir) is a novel imidazopyridine inhibitor of hepatitis C virus (HCV) RNA replication in vitro and has… 
2011
2011
425 FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), ± RBV ± PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPI 1A/1B HCV PATIENTS
2011
2011
Allele-Specific Real-Time PCR System for Detection of Subpopulations of Genotype 1a and 1b Hepatitis C NS5B Y448H Mutant Viruses in Clinical Samples
ABSTRACT The Y448H mutation in NS5B has been selected by GS-9190 as well as several benzothiadiazine hepatitis C virus (HCV… 
2011
2011
1211 EMERGENCE AND PERSISTENCE OF NS5B MUTATIONS FOLLOWING COMBINATION TREATMENT WITH TEGOBUVIR (GS-9190) PLUS STANDARD OF CARE-LONG-TERM FOLLOW-UP FROM THE PHASE IIB STUDY GS-US-196-0103
2011
2011
482 IN VITRO COMBINATION THERAPY WITH TEGOBUVIR (GS-9190) IS HIGHLY EFFICIENT IN CURING CELLS FROM HCV REPLICON AND IN DELAYING/PREVENTING THE DEVELOPMENT OF ANTIVIRAL RESISTANCE
2007
2007
GS-9190, a novel substituted imidazo-pyridine analogue, is a potent inhibitor of hepatitis C virus replication in vitro and remains active against known drug-resistant mutants
2007
2007
Mechanistic characterization of GS-9190, a novel non-nucleoside inhibitor of HCV NS5B polymerase with potent antiviral activity and a unique mechanism of action
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)